Arynta Solution
Product Images NDC 24338-162

Product Visual Gallery

This gallery contains 47 technical images submitted to the FDA as part of the official labeling for Arynta (NDC 24338-162). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Azurity Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Figure 1)

A fold change chart depicting pharmacokinetic parameters (Cmax and AUC) for specific populations including gender, age groups 65-74 years and 75+, and various stages of renal impairment from mild to end-stage renal disease. The chart shows fold changes relative to a reference, with 90% confidence intervals illustrated by horizontal lines around orange diamond markers.*

FDA Label Image

Figure-2 (Figure 2)

A forest plot showing fold changes and 90% confidence intervals in pharmacokinetic parameters Cmax and AUC relative to reference for three drugs: Guanfacine, Venlafaxine, and Omeprazole. The x-axis represents change relative to reference from 0.0 to 2.0, with plotted points and error bars illustrating variability in each parameter for the listed drugs.*

FDA Label Image

Figure-3 (Figure 3)

A graph depicting pharmacokinetic (PK) fold changes with 90% confidence intervals for various interacting drugs, including Guanfacine, Venlafaxine, and substrates of CYP1A2, CYP2D6, CYP2C19, and CYP3A enzymes. The x-axis shows change relative to reference, ranging from 0.0 to 2.0, for parameters Cmax and AUC.*

FDA Label Image

Figure-4 (Figure 4)

A line graph comparing LS Mean (SE) SKAMP Deportment Scores over time post-dose (in hours) for lisdexamfetamine dimesylate versus placebo. The x-axis shows time from -0.5 to 13 hours and the y-axis shows scores from 0.0 to 2.0. Lisdexamfetamine dimesylate scores decrease initially then gradually rise, while placebo scores increase and remain higher throughout most of the period.*

FDA Label Image

Figure-5 (Figure 5)

A line graph depicting the proportion of subjects with relapse or treatment failure over time (days after randomization) comparing lisdexamfetamine dimesylate oral solution to placebo. The x-axis shows time in days, and the y-axis shows the proportion of subjects in percentage. The lisdexamfetamine dimesylate group shows a lower proportion of relapse over time compared to the placebo group.*

FDA Label Image

Figure-6 (Figure 6)

A line graph showing LS Mean (SE) PERMP total scores over time post-dose (hours) comparing lisdexamfetamine dimesylate and placebo. The x-axis represents time from -0.5 to 14 hours, and the y-axis shows scores from 250 to 330. Two lines depict score changes, with lisdexamfetamine dimesylate consistently higher than placebo up to 14 hours post-dose.*

FDA Label Image

Figure-8 (Figure 7)

A Kaplan-Meier curve chart comparing the proportion of subjects with relapse or treatment failure over time (days after randomization) between lisdexamfetamine dimesylate and placebo groups. The x-axis represents time in days, and the y-axis represents the percentage of subjects relapsing or failing treatment, with placebo showing a higher and faster increase than lisdexamfetamine dimesylate.*

FDA Label Image

Figure-8 (Figure 8)

A line chart depicting the proportion of subjects with relapse (%) over time (days after randomization) comparing lisdexamfetamine dimesylate and placebo. Two curves are shown: a solid line for lisdexamfetamine dimesylate with a low, nearly flat relapse rate, and a dashed line for placebo with a steadily increasing relapse rate. Below the x-axis is a table listing the number of subjects at risk for each group at multiple time points.*

FDA Label Image

Ifu Figure-a (Ifu Figure A)

Illustration showing oral dosing supplies for ARYNTA 10 mg/mL solution. It includes a bottle with a child-resistant cap, a detailed oral dosing syringe labeled with volume markings and parts like tip, plunger, barrel, and wrap, and a bottle adapter.*

FDA Label Image

Ifu Figure-b (Ifu Figure B)

An instructional line drawing labeled Figure B shows a pair of hands holding a bottle or container at the top, with liquid droplets and bubbles flowing downward. The image likely demonstrates shaking or mixing the contents of a liquid medication container.*

FDA Label Image

Ifu Figure-c (Ifu Figure C)

An instructional diagram showing steps to open a child-resistant bottle cap. The illustration depicts pressing down on the cap and turning it counterclockwise to open, demonstrating how to properly remove the cap from the bottle.*

FDA Label Image

Ifu Figure-d (Ifu Figure D)

An instructional diagram showing a bottle adapter with a ridged end being placed onto the neck of a bottle. The diagram labels the bottle adapter, ridged end, and bottle neck, illustrating proper attachment of the adapter to the bottle.*

FDA Label Image

Ifu Figure-e (Ifu Figure E)

An illustration showing a graduated oral dosing syringe with volume markings from 1 mL to 7 mL. The syringe is designed for measuring liquid medication doses accurately, likely related to administering ARYNTA (lisdexamfetamine dimesylate) oral solution at 10 mg/mL.*

FDA Label Image

Ifu Figure-f (Ifu Figure F)

An instructional illustration labeled Figure F showing a hand using a plunger to press down on the cap of a bottle, which is being held by another hand. The plunger is indicated with an arrow pointing downward, suggesting how to operate or dispense the solution from the oral medication bottle.*

FDA Label Image

Ifu Figure-g (Ifu Figure G)

An instructional line drawing illustrating a hand holding and preparing to insert a dosing syringe into a bottle opening. The syringe has marked volume graduations visible on its side. This image likely demonstrates how to measure and administer a liquid oral solution dose.*

FDA Label Image

Ifu Figure-h (Ifu Figure H)

An instructional illustration showing how to measure liquid medication using a syringe. The left side depicts drawing liquid from a bottle into a syringe, and the right side shows the syringe barrel marked with volume measurements from 1 mL to 7 mL, with an instruction to measure to the white end of the plunger.*

FDA Label Image

Ifu-figure-hdpe-d (Ifu Figure Hdpe D)

An instructional illustration showing a hand removing a protective seal from the opening of a bottle, demonstrating how to open the ARYNTA lisdexamfetamine dimesylate oral solution container before use.*

FDA Label Image

Ifu-figure-hdpe-e (Ifu Figure Hdpe E)

An instructional illustration labeled 'Figure E' showing a bottle adapter with a ridged end and a bottle neck. The image depicts a hand fitting the bottle adapter onto the bottle neck, demonstrating proper assembly or use of the adapter with the bottle.*

FDA Label Image

Ifu-figure-hdpe-f (Ifu Figure Hdpe F)

An instructional illustration labeled Figure F showing a close-up of a graduated oral dosing syringe with measurement marks from 1 mL to 7 mL. The syringe is intended for precise liquid medication dosing.*

FDA Label Image

Ifu-figure-hdpe-g (Ifu Figure Hdpe G)

Illustration showing a hand holding a bottle of ARYNTA (lisdexamfetamine dimesylate oral solution) while the other hand depresses the plunger of a syringe inserted into the bottle, demonstrating how to draw the medication from the bottle for oral administration.*

FDA Label Image

Ifu-figure-hdpe-h (Ifu Figure Hdpe H)

Illustration showing a hand holding a syringe or oral dosing device being inserted into the neck of a bottle, with volume markings visible on the syringe, demonstrating how to measure and withdraw liquid medication for oral administration.*

FDA Label Image

Ifu-figure-hdpe-i (Ifu Figure Hdpe I)

An instructional diagram showing how to measure a liquid dose using an oral syringe. The left side depicts a person drawing liquid from a vial using the syringe, while the right side highlights measuring the liquid level up to the white end of the plunger at the desired mL marking, ranging from 1 mL to 7 mL.*

FDA Label Image

Ifu-figure-hdpe-j (Ifu Figure Hdpe J)

Illustration showing a person holding a graduated oral syringe with volume markings from 1 mL to 7 mL. The syringe is being measured or filled, demonstrating the proper use of an oral dosing syringe, likely for administering ARYNTA lisdexamfetamine dimesylate oral solution.*

FDA Label Image

Ifu-figure-hdpe-k (Ifu Figure Hdpe K)

An instructional illustration showing a hand removing a syringe from a bottle without touching the plunger. The syringe is held vertically above the bottle, with an arrow indicating upward motion. A cautionary note advises not to touch the plunger when removing the syringe.*

FDA Label Image

Ifu-figure-hdpe-l (Ifu Figure Hdpe L)

Illustration of a dosing syringe featuring volume markings from 1 mL to 7 mL. The syringe is designed for accurate measurement and oral administration of liquid medication, corresponding to the oral solution dosage form.*

FDA Label Image

Ifu-figure-hdpe-m (Ifu Figure Hdpe M)

An instructional line drawing illustration labeled Figure M showing an adult hand administering oral medication to a child using a syringe-like oral dosing device inserted into the child's mouth. The syringe is marked with dose measurements.*

FDA Label Image

Ifu-figure-hdpe-n (Ifu Figure Hdpe N)

An instructional illustration labeled Figure N showing a person administering an oral dosing syringe into the mouth, demonstrating the correct method of delivering a liquid medication orally.*

FDA Label Image

Ifu-figure-hdpe-o (Ifu Figure Hdpe O)

An instructional diagram labeled Figure O, showing a hand gripping and twisting the cap of a small medicine bottle, illustrating how to open the bottle. The image is likely related to ARYNTA lisdexamfetamine dimesylate oral solution usage instructions.*

FDA Label Image

Ifu-figure-hdpe-p (Ifu Figure Hdpe P)

An instructional illustration showing a hand rinsing a syringe in a cup of water on the left, and another hand expelling water from the syringe over a sink on the right. The diagram demonstrates cleaning or rinsing steps for a syringe.*

FDA Label Image

Ifu Figure-i (Ifu Figure I)

An instructional line drawing showing a hand holding an oral dosing syringe with volume markings from 1 mL to 7 mL. The syringe is being prepared for use with a liquid medication, demonstrating how to draw medication into the syringe.*

FDA Label Image

Ifu Figure-j (Ifu Figure J)

An instructional diagram showing a hand removing a syringe from a bottle, with a note advising not to touch the plunger when removing the syringe.*

FDA Label Image

Ifu Figure-k (Ifu Figure K)

An instructional illustration labeled Figure K showing a syringe with measurement markings in milliliters (mL) on the barrel. An arrow points to the markings, indicating measurement of liquid dosage.*

FDA Label Image

Ifu Figure-l (Ifu Figure L)

An instructional line drawing showing a person administering oral medication using a syringe. The syringe tip is in the individual's mouth, demonstrating the oral route for a liquid solution, consistent with the product ARYNTA, lisdexamfetamine dimesylate oral solution.*

FDA Label Image

Ifu Figure-m (Ifu Figure M)

An instructional line drawing showing a person administering an oral solution medication using a syringe. The syringe is positioned near the mouth, indicating the method of dosing the liquid orally.*

FDA Label Image

Ifu Figure-n (Ifu Figure N)

An instructional diagram showing a hand gripping the cap of a small medicine bottle and twisting it in a clockwise direction, illustrating how to open or close the bottle cap.*

FDA Label Image

Ifu Figure-o (Ifu Figure O)

An instructional illustration showing a hand inserting a syringe into a cup containing liquid on the left, and the same syringe being emptied onto a surface on the right. This likely demonstrates the process of measuring and dispensing oral solution dose for ARYNTA (lisdexamfetamine dimesylate).*

FDA Label Image

100ml-carton (Lisdex 10mg 100ml Carton)

Packaging label for ARYNTA oral solution 10 mg/mL, containing lisdexamfetamine dimesylate, by Azurity Pharmaceuticals, Inc. The label shows a 100 mL carton with NDC 24338-019-01, with pharmacy dispensing instructions and storage warnings. It lists included items such as the bottle, oral dosing syringe, and prescribing information. The label emphasizes prescription drug use only.*

FDA Label Image

100ml-label (Lisdex 10mg 100ml Label)

Label for ARYNTA lisdexamfetamine dimesylate oral solution 10 mg/mL by Azurity Pharmaceuticals, Inc. The label includes the drug name, strength, oral use indication, a barcode, and storage instructions. It advises discarding remaining solution 30 days after opening and contains space for recording the bottle opening date. The label also features warnings, recommended dosage referral, and a pharmacist medication guide notice.*

FDA Label Image

Lesidex-10mg-120ml-carton (Lisdex 10mg 120ml Carton)

The packaging label for ARYNTA lisdexamfetamine dimesylate oral solution 10 mg/mL from Azurity Pharmaceuticals, Inc. It includes the product name, strength, dosage form, and quantity of 120 mL. The label indicates the NDC number 24338-162-01 and features storage instructions, warnings, and pharmacy dispensing information. The label also lists included contents such as a bottle, dosing syringe, and medication guide.*

FDA Label Image

Lesidex-10mg-120ml-label (Lisdex 10mg 120ml Label)

ARYNTA 10 mg/mL oral solution label showing lisdexamfetamine dimesylate as the active ingredient. The label includes dosage strength, usage instructions for oral use only, storage conditions, a warning to discard the product 30 days after opening, and pharmacist dispensing instructions. Manufactured by Azurity Pharmaceuticals, Inc., with barcode and refill information.*

FDA Label Image

30ml-carton (Lisdex 10mg 30ml Carton)

Carton label for ARYNTA 10 mg/mL oral solution, containing lisdexamfetamine dimesylate, manufactured by Azurity Pharmaceuticals, Inc. The label includes dosage strength, NDC 24338-103-01, pharmacy dispensing instructions, storage conditions, and a barcode. It mentions the package contains one 30 mL bottle, an oral dosing syringe, and instructions.*

FDA Label Image

Lesidex-10mg-30ml-label (Lisdex 10mg 30ml Label)

Label for ARYNTA 10 mg/mL oral solution containing lisdexamfetamine dimesylate, manufactured by Azurity Pharmaceuticals, Inc. The label includes dosage strength, usage instructions, pharmacist dispensing notice, storage guidelines, and placeholders for the bottle opening date, lot number, and expiration date. The Azurity Pharmaceuticals logo appears on the label.*

FDA Label Image

Lesidex-10mg-60ml-carton (Lisdex 10mg 60ml Carton)

This is a packaging label for ARYNTA oral solution 10 mg/mL, lisdexamfetamine dimesylate, by Azurity Pharmaceuticals, Inc. The carton is for a 60 mL bottle and includes a dosing syringe and bottle adapter. The label highlights storage instructions, warnings, and pharmacist dispensing guidance, with the NDC 24338-160-01 visible.*

FDA Label Image

Lesidex-10mg-60ml-label (Lisdex 10mg 60ml Label)

Label for ARYNTA 10 mg/mL oral solution containing lisdexamfetamine dimesylate, manufactured by Azurity Pharmaceuticals, Inc. The label includes the NDC 24338-160-01, indicates a 60 mL bottle, and provides storage instructions, dosage warnings, and pharmacist dispensing information. It also shows the Azurity Pharmaceuticals logo along with lot and expiration placeholders.*

FDA Label Image

Lesidex-10mg-90ml-carton (Lisdex 10mg 90ml Carton)

Packaging label for ARYNTA 10 mg/mL oral solution (lisdexamfetamine dimesylate) by Azurity Pharmaceuticals, Inc. The label features the proprietary and generic names, the strength of 10 mg/mL, for oral use only, and includes storage instructions, NDC 24338-109-01, and refill and pharmacist dispensing information. The carton indicates it contains one 90 mL bottle and accessories.*

FDA Label Image

Lesidex-10mg-90ml-label (Lisdex 10mg 90ml Label)

Label for ARYNTA 10 mg/mL oral solution containing lisdexamfetamine dimesylate. The label includes dosage information, storage instructions, and a pharmacist advisory to dispense the Medication Guide. It shows the manufacturer as Azurity Pharmaceuticals, Inc., with space for lot number, expiration date, and bottle opening date. The label also features barcodes, the product concentration, and the statement 'For Oral Use Only.'*

FDA Label Image

Lisdex Structure (Lisdex Structure)

Chemical structure of lisdexamfetamine dimesylate, the active ingredient in ARYNTA oral solution 10 mg/mL by Azurity Pharmaceuticals, Inc. The diagram shows the molecular bonds and functional groups characteristic of this compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.